lymphoma, non-Hodgkin, familial

Summary

lymphoma, non-Hodgkin, familial (MONDO:0011508) is a cancer with 4 cohort genes (2 CIViC-evidence somatic drivers; 76 ClinVar predisposition records) and 323 clinical trials. Top therapeutic interventions include plerixafor, tositumomab, and ibrutinib.

At a glance

• Classification: Cancer
• Cohort genes: 4
• ClinVar variants: 76
• Clinical trials: 323

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	lymphoma, non-Hodgkin, familial
Mondo ID	MONDO:0011508
OMIM	605027
SNOMED CT	118601006
UMLS	C4721532
MedGen	1648388
GARD	0024804
Is cancer (heuristic)	yes

Also known as: lymphoma, follicular, somatic · lymphoma, non-Hodgkin · lymphoma, non-Hodgkin, familial · lymphoma, non-Hodgkin, somatic

Data availability: 76 ClinVar variants · 1 GenCC gene-disease record.

Disease family

Classification path: human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › hematopoietic and lymphoid system neoplasm › hematopoietic and lymphoid cell neoplasm › lymphoid neoplasm › lymphoma › non-Hodgkin lymphoma › lymphoma, non-Hodgkin, familial

Related subtypes (9): lymphoblastic lymphoma, lymphosarcoma, acute lymphoblastic leukemia, B-cell non-Hodgkin lymphoma, T-cell non-Hodgkin lymphoma, lung non-Hodgkin lymphoma, ocular adnexal lymphoma, large-cell immunoblastic lymphoma, gastric non-hodgkin lymphoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

ClinVar germline variants

76 retrieved; paginated sample, class counts are floors:

20 uncertain significance, 15 pathogenic/likely pathogenic, 12 conflicting classifications of pathogenicity, 11 likely pathogenic, 9 pathogenic, 6 benign/likely benign, 3 benign

ClinVar	Variant (HGVS)	Gene	Classification	Review
1022083	NM_001083116.3(PRF1):c.895C>T (p.Arg299Cys)	PRF1	Pathogenic/Likely pathogenic	criteria provided, multiple submitters, no conflicts
1067731	NM_001083116.3(PRF1):c.1228C>T (p.Arg410Trp)	PRF1	Pathogenic/Likely pathogenic	criteria provided, multiple submitters, no conflicts
1069592	NM_001083116.3(PRF1):c.1168C>T (p.Arg390Ter)	PRF1	Pathogenic	criteria provided, multiple submitters, no conflicts
1301336	NM_001083116.3(PRF1):c.3G>A (p.Met1Ile)	PRF1	Pathogenic/Likely pathogenic	criteria provided, multiple submitters, no conflicts
13709	NM_001083116.3(PRF1):c.1122G>A (p.Trp374Ter)	PRF1	Pathogenic	criteria provided, multiple submitters, no conflicts
13721	NM_001083116.3(PRF1):c.1090_1091del (p.Leu364fs)	PRF1	Pathogenic	criteria provided, multiple submitters, no conflicts
1406224	NM_001083116.3(PRF1):c.902C>A (p.Ser301Ter)	PRF1	Pathogenic/Likely pathogenic	criteria provided, multiple submitters, no conflicts
2073383	NM_001083116.3(PRF1):c.938A>T (p.Asp313Val)	PRF1	Pathogenic/Likely pathogenic	criteria provided, multiple submitters, no conflicts
2136872	NM_001083116.3(PRF1):c.657C>A (p.Tyr219Ter)	PRF1	Pathogenic/Likely pathogenic	criteria provided, multiple submitters, no conflicts
2498463	NM_001083116.3(PRF1):c.150del (p.Thr51fs)	PRF1	Pathogenic	criteria provided, multiple submitters, no conflicts
2678050	NM_001083116.3(PRF1):c.806_812delinsCC (p.His269fs)	PRF1	Pathogenic/Likely pathogenic	criteria provided, multiple submitters, no conflicts
2678052	NM_001083116.3(PRF1):c.694C>T (p.Arg232Cys)	PRF1	Pathogenic/Likely pathogenic	criteria provided, multiple submitters, no conflicts
2678060	NM_001083116.3(PRF1):c.916G>T (p.Gly306Cys)	PRF1	Pathogenic	criteria provided, multiple submitters, no conflicts
280112	NM_001083116.3(PRF1):c.666C>A (p.His222Gln)	PRF1	Pathogenic/Likely pathogenic	criteria provided, multiple submitters, no conflicts
2844361	NM_001083116.3(PRF1):c.888C>G (p.Tyr296Ter)	PRF1	Pathogenic/Likely pathogenic	criteria provided, multiple submitters, no conflicts
3596513	NM_001083116.3(PRF1):c.284_285del (p.Trp95fs)	PRF1	Pathogenic/Likely pathogenic	criteria provided, multiple submitters, no conflicts
468301	NM_001083116.3(PRF1):c.1349C>T (p.Thr450Met)	PRF1	Pathogenic/Likely pathogenic	criteria provided, multiple submitters, no conflicts
468305	NM_001083116.3(PRF1):c.50del (p.Leu17fs)	PRF1	Pathogenic	criteria provided, multiple submitters, no conflicts
468311	NM_001083116.3(PRF1):c.916G>A (p.Gly306Ser)	PRF1	Pathogenic/Likely pathogenic	criteria provided, multiple submitters, no conflicts
520942	NM_001083116.3(PRF1):c.445G>A (p.Gly149Ser)	PRF1	Pathogenic	criteria provided, multiple submitters, no conflicts
802582	NM_001083116.3(PRF1):c.659G>A (p.Gly220Asp)	PRF1	Pathogenic/Likely pathogenic	criteria provided, multiple submitters, no conflicts
802583	NM_001083116.3(PRF1):c.160C>T (p.Arg54Cys)	PRF1	Pathogenic/Likely pathogenic	criteria provided, multiple submitters, no conflicts
961631	NM_001083116.3(PRF1):c.658G>A (p.Gly220Ser)	PRF1	Pathogenic	criteria provided, multiple submitters, no conflicts
971288	NM_001083116.3(PRF1):c.844AAG[3] (p.Lys285del)	PRF1	Pathogenic	criteria provided, multiple submitters, no conflicts
1012308	NM_001083116.3(PRF1):c.147C>A (p.Asp49Glu)	PRF1	Likely pathogenic	criteria provided, multiple submitters, no conflicts
1039229	NM_001083116.3(PRF1):c.1471G>A (p.Asp491Asn)	PRF1	Likely pathogenic	criteria provided, multiple submitters, no conflicts
3596457	NM_001083116.3(PRF1):c.1179C>A (p.Cys393Ter)	PRF1	Likely pathogenic	criteria provided, single submitter
3596496	NM_001083116.3(PRF1):c.730_731delinsG (p.Leu244fs)	PRF1	Likely pathogenic	criteria provided, single submitter
3596505	NM_001083116.3(PRF1):c.457C>T (p.Gln153Ter)	PRF1	Likely pathogenic	criteria provided, single submitter
3596509	NM_001083116.3(PRF1):c.387G>A (p.Trp129Ter)	PRF1	Likely pathogenic	criteria provided, single submitter

Genes & proteins

Mendelian disease overlap and somatic drivers

GenCC: 6 · Orphanet: 6 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0

Somatic driver evidence (intOGen + CIViC, cohort fanout)

Gene	intOGen role	Cancer types	CIViC
RAD54L			CIViC #6676
BCL10	LoF	DLBCLNOS,MLYM	CIViC #7074

GenCC gene–disease validity (cohort genes)

the Disease column is the GenCC-asserted condition — a cohort gene’s strongest validity may be for a related predisposition syndrome.

Gene	Classification	Inheritance	Disease	Records
PRF1	Limited	Unknown	lymphoma, non-Hodgkin, familial	6

Orphanet rare-disease linkage (cohort genes)

Gene	Orphanet ID	Rare disease
PRF1	Orphanet:391343	Fatal post-viral neurodegenerative disorder
PRF1	Orphanet:540	Familial hemophagocytic lymphohistiocytosis
PRF1	Orphanet:88	Idiopathic aplastic anemia
CASP10	Orphanet:3261	Autoimmune lymphoproliferative syndrome
RAD54L	Orphanet:227535	Hereditary breast cancer
BCL10	Orphanet:52417	MALT lymphoma

Cohort genes → proteins

4 cohort genes, 4 distinct canonical proteins.

Evidence partition

Subset	Genes
multi_evidence	4

Cohort genes (full)

Symbol	HGNC	Ensembl	UniProt	Name	Evidence
PRF1	HGNC:9360	ENSG00000180644	P14222	Perforin-1	gencc,clinvar
CASP10	HGNC:1500	ENSG00000003400	Q92851	Caspase-10	clinvar
RAD54L	HGNC:9826	ENSG00000085999	Q92698	DNA repair and recombination protein RAD54-like	clinvar
BCL10	HGNC:989	ENSG00000142867	O95999	B-cell lymphoma/leukemia 10	clinvar

Cohort function summary

Lead sentence per gene, UniProt-curated.

Symbol	Protein name	Function (lead sentence)
PRF1	Perforin-1	Pore-forming protein that plays a key role in granzyme-mediated programmed cell death, and in defense against virus-infected or neoplastic cells.
CASP10	Caspase-10	Involved in the activation cascade of caspases responsible for apoptosis execution.
RAD54L	DNA repair and recombination protein RAD54-like	Multifunctional ATPase that plays a role in homologous recombination (HR) which is a major pathway for repairing DNA double-strand breaks (DSBs), single-stranded DNA (ssDNA) gaps, and stalled or collapsed replication forks.
BCL10	B-cell lymphoma/leukemia 10	Plays a key role in both adaptive and innate immune signaling by bridging CARD domain-containing proteins to immune activation.

Protein-family classification

Druggable: 3 · Difficult: 0 · Unknown: 1 · Druggable fraction: 0.75

Family distribution

Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.

Family	Genes	Fold	FDR
Complement	1	67.0×	0.045
Enzyme (other)	2	6.0×	0.056
Other/Unknown	1	0.5×	0.962

Per-gene assignment

Symbol	Family	Druggable?	EC	InterPro (top 3)
PRF1	Complement	yes		C2_dom, MACPF_CS, MACPF
CASP10	Enzyme (other)	yes	3.4.22.63	Pept_C14_p20, DED_dom, Pept_C14_p10
RAD54L	Enzyme (other)	yes	3.6.4.B9	SNF2_N, Helicase_C-like, Helicase_ATP-bd
BCL10	Other/Unknown	no		CARD, DEATH-like_dom_sf, BCL10/E10

Expression context

Cohort genes with no expression data: 0.

3 cohort genes are a single-cell marker in ≥1 SCXA experiment.

Breadth distribution (Bgee present_calls)

Bucket	Genes
narrow (1-5 tissues)	0
moderate (6-20)	0
broad (>20)	4
unknown	0

Top tissues across cohort

Tissue	Cohort genes
granulocyte	2
blood	1
spleen	1
colonic epithelium	1
monocyte	1
left testis	1
right testis	1
ventricular zone	1
esophagus squamous epithelium	1
mucosa of sigmoid colon	1
squamous epithelium	1

Per-gene tissue summary (top 30)

Symbol	Bgee breadth	FANTOM5 breadth	SCXA	Top tissues
PRF1	220	broad	marker	granulocyte, blood, spleen
CASP10	206	ubiquitous	marker	colonic epithelium, granulocyte, monocyte
RAD54L	173	ubiquitous	yes	left testis, right testis, ventricular zone
BCL10	280	ubiquitous	marker	esophagus squamous epithelium, mucosa of sigmoid colon, squamous epithelium

Protein interactions among cohort

Intra-cohort edges: 0.

Hub genes (top 10 by interactor count)

Symbol	Interactor count
PRF1	3,299
RAD54L	2,927
BCL10	1,873
CASP10	1,242

Structural data

PDB: 2 · AlphaFold-only: 2 · No structure: 0

Cohort genes with PDB structures (top 30)

Symbol	UniProt	PDB entries
BCL10	O95999	5
RAD54L	Q92698	1

AlphaFold-only cohort genes (top 30 by pLDDT)

Symbol	UniProt	pLDDT
PRF1	P14222	91.01
CASP10	Q92851	69.54

Function

Pathway analysis

Distinct Reactome pathways touched by cohort: 29. Enrichment computed across 4 evidence-associated genes (3 with Reactome annotation).

Pathways by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 3 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

Pathway	Cohort genes	Fold	FDR	Sample cohort genes
FasL/ CD95L signaling	1	761.3×	0.018	CASP10
TRAIL signaling	1	475.8×	0.018	CASP10
TP53 Regulates Transcription of Caspase Activators and Caspases	1	317.2×	0.018	CASP10
NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10	1	292.8×	0.018	CASP10
Downstream signaling events of B Cell Receptor (BCR)	1	271.9×	0.018	BCL10
Protein ubiquitination	1	271.9×	0.018	BCL10
Innate Immune System	2	17.0×	0.019	CASP10, BCL10
TP53 Regulates Transcription of Cell Death Genes	1	181.3×	0.019	CASP10
TCR signaling	1	165.5×	0.019	BCL10
Signaling by the B Cell Receptor (BCR)	1	115.3×	0.024	BCL10
Nuclear events stimulated by ALK signaling in cancer	1	108.8×	0.024	PRF1
Fc epsilon receptor (FCERI) signaling	1	90.6×	0.026	BCL10
DDX58/IFIH1-mediated induction of interferon-alpha/beta	1	84.6×	0.026	CASP10
C-type lectin receptors (CLRs)	1	79.3×	0.026	BCL10
Activation of NF-kappaB in B cells	1	65.6×	0.028	BCL10
E3 ubiquitin ligases ubiquitinate target proteins	1	64.5×	0.028	BCL10
Immune System	2	8.6×	0.029	CASP10, BCL10
FCERI mediated NF-kB activation	1	52.1×	0.031	BCL10
CLEC7A (Dectin-1) signaling	1	47.6×	0.031	BCL10
Death Receptor Signaling	1	46.4×	0.031	CASP10
Downstream TCR signaling	1	42.8×	0.032	BCL10
Transcriptional Regulation by TP53	1	20.7×	0.063	CASP10
Adaptive Immune System	1	9.9×	0.123	BCL10
RNA Polymerase II Transcription	1	7.5×	0.154	CASP10
Post-translational protein modification	1	6.4×	0.172	BCL10
Gene expression (Transcription)	1	6.0×	0.177	CASP10
Generic Transcription Pathway	1	5.0×	0.200	CASP10
Metabolism of proteins	1	4.1×	0.231	BCL10
Signal Transduction	1	3.4×	0.267	CASP10

GO biological processes by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 4 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

GO term	Cohort genes	Fold	FDR	Sample cohort genes
cellular defense response	2	159.0×	0.004	PRF1, BCL10
positive regulation of killing of cells of another organism	1	4213.0×	0.005	PRF1
protein maturation	2	81.8×	0.005	PRF1, CASP10
protein homooligomerization	2	61.1×	0.006	PRF1, BCL10
immune response to tumor cell	1	1404.3×	0.007	PRF1
positive regulation of lymphotoxin A production	1	1404.3×	0.007	BCL10
negative regulation of mature B cell apoptotic process	1	1053.2×	0.007	BCL10
double-strand break repair via synthesis-dependent strand annealing	1	1053.2×	0.007	RAD54L
positive regulation of mast cell cytokine production	1	842.6×	0.007	BCL10
positive regulation of canonical NF-kappaB signal transduction	2	36.3×	0.007	CASP10, BCL10
granzyme-mediated programmed cell death signaling pathway	1	526.6×	0.010	PRF1
protein import	1	421.3×	0.010	PRF1
quinolinate biosynthetic process	1	383.0×	0.010	BCL10
B cell apoptotic process	1	351.1×	0.010	BCL10
immunological synapse formation	1	324.1×	0.010	PRF1
defense response to tumor cell	1	324.1×	0.010	PRF1
programmed cell death	1	324.1×	0.010	BCL10
T cell apoptotic process	1	324.1×	0.010	BCL10
protein transmembrane transport	1	324.1×	0.010	PRF1
T cell mediated cytotoxicity	1	280.9×	0.011	PRF1
antifungal innate immune response	1	234.1×	0.012	BCL10
non-canonical NF-kappaB signal transduction	1	210.7×	0.012	BCL10
positive regulation of phosphorylation	1	210.7×	0.012	BCL10
positive regulation of execution phase of apoptosis	1	210.7×	0.012	CASP10
positive regulation of T cell receptor signaling pathway	1	191.5×	0.013	BCL10
immunoglobulin mediated immune response	1	175.5×	0.013	BCL10
toll-like receptor signaling pathway	1	150.5×	0.014	BCL10
plasma membrane repair	1	145.3×	0.014	PRF1
chromosome organization	1	145.3×	0.014	RAD54L
reciprocal meiotic recombination	1	140.4×	0.014	RAD54L

Therapeutics

Drug target analysis

Approved (phase 4): 0 · Phase ≥3: 0 · Phased (≥1): 1 · Undrugged: 3

Druggability breadth: 3 of 4 evidence-associated genes (75%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).

Top cohort targets by molecule count

Symbol	Molecules	Max phase
RAD54L	1	2
PRF1	0	0
CASP10	0	0
BCL10	0	0

Drugs targeting cohort genes (top 30)

Molecule	Max phase	Targets in cohort
STREPTONIGRIN	2	RAD54L

Bioactivity and enzyme data

Enzyme cohort genes (≥1 EC): 2.

Cohort genes with ChEMBL bioactivity (full, sorted by assay count)

Symbol	Assays	Type breakdown
PRF1	34	Binding:34
CASP10	22	Binding:21, Functional:1
RAD54L	3	Functional:2, Binding:1

Cohort enzymes (BRENDA EC)

Symbol	EC numbers	Names
CASP10	3.4.22.63	caspase-10
RAD54L	3.6.4.B9

Pharmacogenomics

Cohort genes with a PharmGKB record: 4; with CPIC/DPWG dosing guidelines: 0.

No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).

Drug repurposing candidates

1 approved/phased drugs hit cohort targets but don’t yet appear in disease-level clinical trials. Target-inhibition rationale is strongest for cancer driver genes; a bioactivity hit is a screening signal, not a treatment claim.

Compound	Max phase	Cohort target (bioactivity)
STREPTONIGRIN	2	RAD54L

Druggability pyramid

Cohort genes binned by druggability tier (high → low):

Tier	Definition	Genes	Symbols
A	Approved (phase 4 drug)	0
B	Phased (≥1) drug, not yet approved	1	RAD54L
C	Druggable family + PDB, no drug	0
D	Druggable family + AlphaFold only, no drug	2	PRF1, CASP10
E	Difficult family or no structure, no drug	1	BCL10

Undrugged target profiles

3 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).

Symbol	ChEMBL assays	Drugged partners (top 3)
PRF1	34	—
CASP10	22	—
BCL10	0	—

Clinical trials & evidence

Clinical trials

Clinical trials: 323.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE1	95
PHASE2	92
Not specified	65
PHASE1/PHASE2	39
PHASE3	24
PHASE4	5
PHASE2/PHASE3	2
EARLY_PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03229200	PHASE4	ACTIVE_NOT_RECRUITING	Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib.
NCT04460235	PHASE4	RECRUITING	Clinical Trial Assessing the Immunogenicity of an Anti-pneumococcal Vaccination Strategy (PCV13+PPV23 Versus PREVENAR20) in Adult Patients Treated for a Lymphoma
NCT00114348	PHASE4	COMPLETED	ALL-REZ BFM 2002: Multi-Center Study for Children With Relapsed Acute Lymphoblastic Leukemia
NCT00168727	PHASE4	COMPLETED	Zevalin® Followed by Rituxan® Maintenance in Previously Treated Low Grade Non-Hodgkin’s Lymphoma
NCT04083079	PHASE4	UNKNOWN	Cost-Effectiveness Study of PEG-rhG-CSF in Prophylactic Treatment of Neutropenia After Chemotherapy in Lymphoma
NCT03480360	PHASE3	ACTIVE_NOT_RECRUITING	Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators’ Expression
NCT05556720	PHASE3	ACTIVE_NOT_RECRUITING	Bringing Optimised COVID-19 Vaccine Schedules To ImmunoCompromised Populations (BOOST-IC): an Adaptive Randomised Controlled Clinical Trial
NCT00000658	PHASE3	COMPLETED	A Phase III Randomized Trial of Low-Dose Versus Standard-Dose mBACOD Chemotherapy With rGM-CSF for Treatment of AIDS-Associated Non-Hodgkin’s Lymphoma
NCT00006434	PHASE3	COMPLETED	Tumor Lysate Pulsed-Dendritic Cell Vaccines After High-Dose Chemotherapy for Non-Hodgkin’s Lymphoma
NCT00045877	PHASE2/PHASE3	COMPLETED	Proleukin in Combination With Rituxan in Patients With Low-Grade Non-Hodgkin’s Lymphoma Who Have Previously Failed Rituxan Treatments
NCT00088530	PHASE3	COMPLETED	BBR 2778 for Relapsed, Aggressive Non-Hodgkin’s Lymphoma (NHL)
NCT00103610	PHASE3	COMPLETED	Mobilization of Stem Cells With AMD3100 (Plerixafor) in Non-Hodgkin’s Lymphoma Patients
NCT00154440	PHASE3	UNKNOWN	Helicobacter - Lymphoma - Radiation Part I: Eradication, Part II: Radiation
NCT00185393	PHASE3	COMPLETED	Treatment With [90]Y-Ibritumomab Tiuxetan Versus no Treatment in Patients With Follicular Non Hodgkin Lymphoma (Stage III or IV) Having Achieved a Partial or Complete Remission After First Line Chemotherapy
NCT00186823	PHASE3	COMPLETED	Haploidentical Stem Cell Transplantation for Patients With Hematologic Malignancies
NCT00261677	PHASE3	COMPLETED	A Study to Evaluate the Effect of Weekly PROCRIT (Epoetin Alfa) or Placebo on Anemia and Quality of Life in Children With Cancer Undergoing Chemotherapy
NCT00268983	PHASE3	COMPLETED	Comparison Of Rituximab Versus Tositumomab and Iodine I 131 Tositumomab (BEXXAR® Therapeutic Regimen) For Patients With Relapsed Follicular Non-Hodgkins Lymphoma
NCT00319332	PHASE3	WITHDRAWN	A Comparative Study Of Iodine I 131 Tositumomab Therapeutic Regimen Versus Ibritumomab Tiuxetan Therapeutic Regimen
NCT00329030	PHASE3	COMPLETED	Rituxan/BEAM vs Bexxar/BEAM in Autologous Hematopoietic Stem Cell Transplant for Non-Hodgkin’s Lymphoma (BMTCTN0401)
NCT01232556	PHASE3	TERMINATED	A Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose Chemotherapy
NCT01938001	PHASE3	COMPLETED	Rituximab Plus Lenalidomide for Patients With Relapsed / Refractory Indolent Non-Hodgkin’s Lymphoma (Follicular Lymphoma and Marginal Zone Lymphoma)
NCT01987505	PHASE3	COMPLETED	MabRella Study: A Study to Evaluate the Safety of Switching From Intravenous to Subcutaneous Administration of Rituximab During First-Line Treatment for Lymphoma
NCT01996865	PHASE3	COMPLETED	Lenalidomide Plus Rituximab Followed by Lenalidomide Versus Rituximab Maintenance for Relapsed/Refractory Follicular, Marginal Zone or Mantle Cell Lymphoma.
NCT02369016	PHASE3	COMPLETED	Phase III Copanlisib in Rituximab-refractory iNHL
NCT02417129	PHASE3	TERMINATED	BI 695500 vs Rituxan First Line Treatment in Patients With Low Tumor Burden Follicular Lymphoma
NCT02626455	PHASE3	TERMINATED	Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin’s Lymphoma (iNHL)
NCT02703272	PHASE3	TERMINATED	A Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Participants With Relapsed or Refractory Mature B-cell Non-Hodgkin Lymphoma
NCT02747043	PHASE3	COMPLETED	Study to Assess if ABP798 is Safe & Effective in Treating Non Hodgkin Lymphoma Compared to Rituximab
NCT03366272	PHASE2/PHASE3	COMPLETED	Nivolumab With Gemcitabine, Oxaliplatin + Rituximab in r/r Elderly Lymphoma Patients
NCT03575351	PHASE3	COMPLETED	A Study to Compare the Efficacy and Safety of JCAR017 to Standard of Care in Adult Subjects With High-risk, Transplant-eligible Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphomas
NCT05431179	PHASE3	WITHDRAWN	A Study of Zilovertamab and Ibrutinib in Patients With Relapsed or Refractory Mantle Cell Lymphoma
NCT00882895	PHASE2	ACTIVE_NOT_RECRUITING	Tandem Stem Cell Transplantation for Non-Hodgkin’s Lymphoma
NCT02497898	PHASE2	NOT_YET_RECRUITING	Treatment of CIK for Patients With Refractory Non-Hodgkin Lymphoma
NCT02690545	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING	Study of CD30 CAR for Relapsed/Refractory CD30+ HL and CD30+ NHL
NCT02693535	PHASE2	RECRUITING	TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
NCT03297606	PHASE2	RECRUITING	Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)
NCT03301168	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING	Study of Gene Modified Donor T-cells Following TCR Alpha Beta Positive Depleted Stem Cell Transplant
NCT03930953	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING	A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL)
NCT04077723	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING	A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Englumafusp Alfa in Combination With Obinutuzumab and in Combination With Glofitamab Following a Pre-Treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin’s Lymphoma
NCT04245839	PHASE2	ACTIVE_NOT_RECRUITING	A Study to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL)

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
PLERIXAFOR	4	10
TOSITUMOMAB	4	9
IBRUTINIB	4	6
2-MERCAPTOETHANESULFONIC ACID	4	4
BENDAMUSTINE	4	4
FILGRASTIM	4	4
BLEOMYCIN SULFATE	4	3
BRENTUXIMAB VEDOTIN	4	3
CARMUSTINE	4	3
CYCLOPHOSPHAMIDE ANHYDROUS	4	3
LEUCOVORIN	4	3
OBINUTUZUMAB	4	3
OFATUMUMAB	4	3
PIRTOBRUTINIB	4	3
VINCRISTINE	4	3
YTTRIUM Y 90 IBRITUMOMAB TIUXETAN	4	3
DIPHENHYDRAMINE	4	2
ETOPOSIDE PHOSPHATE	4	2
GLOFITAMAB	4	2
IDELALISIB	4	2
LENALIDOMIDE	4	2
PIXANTRONE	4	2
RELATLIMAB	4	2
RITUXIMAB	4	2
THIOTEPA	4	2
ABEMACICLIB	4	1
ALLOPURINOL	4	1
ASPARAGINASE	4	1
AXITINIB	4	1
BORTEZOMIB D-MANNITOL	4	1